Home
About BioSig
Overview
Leadership
Partnerships
PURE EP
Our Solution
Publications
Physician Insights
Join Our Team
News & Media
Overview
Press Releases
BioSig in the News
Presentations
Events
Newsletter
Investors
Investor Relations
Overview
News / Events
Press Releases
IR Calendar
Email Alerts
Company Info
Profile
Presentations
Management Team
Contacts
FAQ
Financial Info
Balance Sheet
Income Statement
Cash Flow
Financial Results
Stock Data
Quote
Charts
Historical Data
Analyst Coverage
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Governance
Board of Directors
Board Committees
Governance Documents
Contact
Investors
Investors
Overview
News / Events
Press Releases
IR Calendar
Email Alerts
Company Info
Profile
Presentations
Management Team
Contacts
FAQ
Financial Info
Balance Sheet
Income Statement
Cash Flow
Financial Results
Stock Data
Quote
Charts
Historical Data
Analyst Coverage
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Governance
Board of Directors
Board Committees
Governance Documents
Investor Tools
Email Alerts
Fact Sheet
Contacts
RSS News Feed
Presentations
Company Information
Profile
Presentations
Management Team
Contacts
FAQ
Corporate Summary
March 20, 2023
Investor Presentation
February 3, 2023
Shareholder Letter
May 11, 2022
NobleCon18 Capital Markets Conference
April 20, 2022
BioSig Technologies Conference Call
December 23, 2021
BioSig Unblinding of Clinical Data
July 26, 2021
Shareholder Letter
March 29, 2021
BioSig Business Development Update Telebriefing Transcript
November 18, 2020
PURE EP Update Telebriefing Transcript
September 17, 2020
Innovation in Signal Acquisition and Processing Unblinding Pure EP
September 15, 2020
